AWT 030
Alternative Names: AWT-030Latest Information Update: 16 Jun 2023
At a glance
- Originator Anwita Biosciences
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 21 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Jun 2023 Anwita Biosciences has patent pending for Cytokine fusion proteins and uses thereof
- 14 Apr 2023 Preclinical trials in Cancer in USA (Parenteral) prior to April 2023
- 14 Apr 2023 Pharmacodynamics and adverse event data from the preclinical studies presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)